| Ytd | -50.51% | |
| 1y | -36.65% |
| Open | 1.44 | Prev Close | 1.44 | Low | 1.39 | High | 1.46 | Mkt Cap | 24.21M |
| Vol | 24.95K | Avg Vol | 52.62K | EPS | 0.12 | P/E | 12.38 | Forward P/E | N/A |
| Beta | 0.27 | Short Ratio | 3.42 | Inst. Own | 0.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.62 | 200-d Avg | 2.01 | 1yr Est | 0.00 |
BCG News
Christoph Schweizer, CEO of Boston Consulting Group (BCG), tells CNBC's Squawk Box Europe that AI ad
enGene Therapeutics Inc. (Nasdaq: ENGN, âenGeneâ or the âCompanyâ), a clinical-stage, non-vi
SAN FRANCISCO--(BUSINESS WIRE)--Transcend, the autonomous "can I use this data?" platform that power
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus
TVS Motor Company, part of TVS VENU, has been ranked #1 globally in the âDurable Consumer Goods' c
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today annou
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a vertically integrated commercial-stage immunotherap
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a vertically integrated commercial-stage immunotherap
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today annou
- Assets Under Management (“AuM”) Increased 12.9% Year-over-Year to $29.0 Billion - - Increased Net
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the IT
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-mo
More than 90% of patients surveyed who underwent bladder removal or received BCG report negative imp
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in
Binah Capital Group, Inc. (NASDAQ: BCG - Get Free Report)'s stock price fell 9% during mid-day tradi
Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 result
– Grew Total Revenue 11% Year-over-Year to $187.1 Million – – Assets Under Management (“AuM”) Increa
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC